Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO

Min, Ju Hong; Waters, Patrick; Vincent, Angela; Lee, S.; Shin, Hee Young; Lee, K. H.; Kim, B. J.

doi:10.1111/j.1600-0404.2012.01643.x

Cited by 15 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Follow-up liver function tests and routine blood tests revealed immediate liver function damage followed by recovery, consistent with the findings of a study by Chen et al (23). IRE causes significant abnormalities in liver function; however, in the majority of patients these are self-limiting, do not preclude treatment and resemble the changes observed following radiofrequency ablation or cryoablation of the liver (24). IRE for the treatment of liver cancer is associated with hepatocyte destruction and the subsequent release of transaminases and bilirubin, which are considered as important markers of hepatic functional reserve (25).…”

Section: Discussionsupporting

confidence: 89%

Irreversible electroporation of malignant liver tumors: Effect on laboratory values

et al. 2018

View full text Add to dashboard Cite

Liver cancer is often associated with chronic liver diseases. Treatment with percutaneous irreversible electroporation (IRE) may preserve liver function. In the present study, the clinical data of 29 patients with liver tumors between July 2015 and December 2016, all of whom underwent liver IRE at Fuda Cancer Hospital, Guangzhou, China was retrospectively reviewed. All the patients survived the treatment. Of the 29 patients, 7 were positive for hepatitis B, 15 had hepatocellular carcinoma (HCC) and 7 had pancreatic cancer with liver metastases. All patients survived IRE. Despite liver-protective treatment prior to IRE, the mean alanine transaminase (ALT) and aspartate transaminase (AST) levels were significantly elevated 1-2 days after IRE, to 540 and 712 U/l, respectively; however they had returned to the preoperative values by 2 weeks following IRE. Prior to IRE, the mean total bilirubin and direct bilirubin measurement levels were normal; however, 8-10 days after IRE, they had increased to 24 U/l and 12 µmol/l, respectively, and had returned back to the preoperative levels by 2 weeks after IRE. This first group included all patients. The result of the 4 subgroups of cancer patients demonstrated a variation between different measurement days and recovery with patients positive for the hepatitis B virus taking the longest duration to recover (17±3 days) meanwhile patients with pancreatic cancer with liver metastases took the shortest time to achieve recovery (10.78±2 days). The findings of the present study indicate that hepatic injury caused by IRE is transient and self-limiting in patients with liver tumors.

show abstract

Section: Discussionsupporting

confidence: 89%

Irreversible electroporation of malignant liver tumors: Effect on laboratory values

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In a congenital glaucomatic rabbit model, UA levels in the aqueous humor have been found to be significantly lower compared with age-matched controls (17.1 ± 3.2 and 189.1 ± 75.70 μ M/mg, respectively) [27]. Several studies have also reported that UA levels in patients with neuromyelitis optica were significantly lower compared with healthy control subjects [46, 47]. With the focus more on eyes and their nerves, these findings directly support our results in that subjects with a lower baseline serum UA level have a higher probability of experiencing glaucomatous progression during the follow-up period.…”

Section: Discussionmentioning

confidence: 99%

Association between Pretreatment Serum Uric Acid Levels and Progression of Newly Diagnosed Primary Angle-Closure Glaucoma: A Prospective Cohort Study

Shao

Cao

et al. 2019

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Purpose. Increased evidence reveals that uric acid (UA) may have an important neuroprotective effect through its antioxidant properties. The aim of the present study was to investigate the relationship between pretreatment serum UA levels and the progression of newly diagnosed primary angle-closure glaucoma (PACG). Methods. This prospective observational cohort study included 64 patients with newly diagnosed PACG who were followed up for a mean period of 12.77 months (range: 3–28 months). All subjects underwent a complete ophthalmological examination during the baseline and final follow-up visits, together with the acquisition of blood samples for UA measurements. During the follow-up period, the progression of PACG was defined as a clinical diagnosis of medically uncontrolled intraocular pressure and a loss of visual field with a mean deviation of >1 dB/year. Univariable and multivariable Cox regression models were used to investigate the association between baseline serum UA levels and the progression of PACG. The cumulative probability of progression of glaucoma was analyzed using the Kaplan-Meier method. Results. During follow-up, 32 subjects were defined as progressive PACG, among whom baseline UA values were significantly higher in nonprogressing subjects than in progressing subjects (0.314±0.069 mmol/l versus [vs.] 0.258±0.069 mmol/l, respectively; P=0.002). Similar results were also observed in male and female subgroups (P<0.05). In a multivariable model, a decreased baseline serum UA level was associated with an increased risk for progressing PACG: both in male (hazard ratio [HR] 6.088 [95% confidence interval (CI) 1.163–31.8638]; P=0.032) and female subjects (HR 3.565 [95% CI 1.131–11.236]; P=0.030). Subjects with high UA levels demonstrated higher cumulative probabilities of nonprogressing PACG than those with low UA levels (male [16.67% vs. 80.00%; P=0.0084] and female [29.41% vs. 68.00%; P=0.0182]). Conclusion. An association between high baseline serum UA levels and a decreased risk for progressing PACG was found. This primary finding suggests that high serum UA levels may have a protective role against PACG and could slow disease progression.

show abstract

“…Min et al. (2012) suggest that serum UA levels decrease in NMO patients during relapse compared with healthy subjects, but then normalize during remission, which suggests that serum UA levels are associated with clinical disease status in NMO patients. In the present paper, CSF UA levels were significantly increased, and serum UA levels were mildly elevated in NMOSD patients during relapse compared with patients with noninflammatory and non‐neurodegenerative diseases, although CSF and serum UA levels were not measured during remission.…”

Section: Discussionmentioning

confidence: 99%

“…Oxidative stress is also thought to be involved in NMO and MS (Gonsette, 2008; Haider, 2015; Lassmann & van Horssen, 2016; Penton‐Rol et al., 2009). Previous studies have focused more on serum UA in NMO/MS patients (Ashtari, Bahar, Aghaei, & Zahed, 2013; Liu et al., 2013; Min et al., 2012; Peng et al., 2008; Sotgiu et al., 2002), although cerebrospinal fluid (CSF) UA levels might more directly reflect CNS. However, very little is known about CSF UA levels in NMOSDs.…”

Section: Introductionmentioning

confidence: 99%

Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders

Shu

Zhang

et al. 2016

Brain and Behavior

View full text Add to dashboard Cite

IntroductionPrevious studies have shown that serum uric acid (UA) modulates outcomes of neurological diseases, although little is known about cerebrospinal fluid (CSF) UA levels in neuromyelitis optica spectrum disorders (NMOSDs).MethodsCerebrospinal fluid and serum UA levels were measured in samples from 68 patients, including NMOSDs during relapse (n = 38) and controls with noninflammatory and non‐neurodegenerative diseases (CTLs, n = 30). Correlation analysis was performed between CSF UA and clinical characteristics, serum UA, and blood–brain barrier integrity in NMOSDs.ResultsCerebrospinal fluid UA levels in NMOSDs were significantly higher than in CTLs (p = .002), while serum UA differences between NMOSDs and CTLs were not statistically significant. In NMOSDs, CSF UA levels were significantly higher in patients with an impaired blood–brain barrier than in patients with an intact one (p < .001), and significantly higher in longer disease duration than in shorter disease duration patients (p = .002). CSF UA levels were also significantly higher in active patients upon MRI than in inactive patients (p < .001), and significantly higher in patients with brain lesions than without brain lesions (p = .024). CSF UA was significantly associated with the serum UA levels (r = .454, p = .002), disease duration (r = .383, p = .018), and blood–brain barrier index (r = .805, p < .001), but did not correlate with age, gender, annualized relapse rate, duration, or severity of NMOSD. Multiple regression analysis demonstrated that CSF UA was independent of the blood–brain barrier index (β = .765, p < .001) and serum UA levels (β = .01, p = .019) in NMOSDs.ConclusionsCerebrospinal fluid UA levels were elevated in NMOSD patients during relapse, and were likely modified by serum UA levels and blood–brain barrier integrity.

show abstract

Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO

Abstract: UA levels are associated with clinical disease status in patients with NMO. Further investigations are recommended to elucidate the role of UA as a biomarker of disease activity in NMO.

Cited by 15 publications

References 24 publications

Irreversible electroporation of malignant liver tumors: Effect on laboratory values

Irreversible electroporation of malignant liver tumors: Effect on laboratory values

Association between Pretreatment Serum Uric Acid Levels and Progression of Newly Diagnosed Primary Angle-Closure Glaucoma: A Prospective Cohort Study

Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders

Contact Info

Product

Resources

About